What's new in neuromuscular disorders? The congenital myopathies

European Journal of Paediatric Neurology

Volumn 7, Issue 1, 2003, Pages 23-30

  Jungbluth, Heinz ^a,b   Sewry, Caroline A ^a,c   Muntoni, Francesco ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c ROBERT JONES AND AGNES HUNT ORTHOPAEDIC HOSPITAL   (United Kingdom)

Author keywords

Central core disease; Genetics; Multi minicore disease; Myotubular myopathy; Nemaline myopathy; Pathophysiology

Indexed keywords

NEBULIN; RYANODINE RECEPTOR; SELENOPROTEIN; TROPOMYOSIN; TROPONIN T;

CENTRAL CORE DISEASE; CENTRONUCLEAR MYOPATHY; CHILD; DISEASE COURSE; GENE MUTATION; GENETIC DISORDER; HUMAN; INFANT; MULTIMINICORE DISEASE; MUSCLE BIOPSY; MYOPATHY; NEMALINE MYOPATHY; NEUROMUSCULAR DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SYMPTOMATOLOGY;

EID: 0037215787     PISSN: 10903798     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1090-3798(02)00136-8     Document Type: Review

References (76)

1. Shy GM, Magee KR. A new congenital non-progressive myopathy. Brain 1956;79:610-21.
2. Shy GM, Engel WK, Somers JE, Wanko T. Nemaline myopathy. A new congenital myopathy. Brain 1963;86:793-810.
3. Spiro AJ, Shy GM, Gonatas NK. Myotubular myopathy. Arch Neurol 1966;14:1-14.
4. Engel AG, Gomez MR, Groover RV. Multicore disease. A recently recognized congenital myopathy associated with multifocal degeneration of muscle fibers. Mayo Clin Proc 1971;46:666-81.
5. Goebel HH, Anderson JR, Huebner C et al. Congenital myopathy with excess thin myofilaments. Neuromusc Disord 1997;7:160-8.
6. Monnier N, Romero NB, Lerale J et al. An autosomal dominant congenital myopathy with cores and rods is associated with a neomutation in the RYR1 encoding the skeletal muscle ryanodine receptor. Hum Mol Genet 2000;9:2599-608.
7. Jungbluth H, Sewry CA, Brown SC et al. Mild phenotype of nemaline myopathy with sleep hypoventilation due to mutation in the skeletal muscle α-actin (ACTA1) gene. Neuromusc Disord 2001;11:35-40.
8. Lammens M, Moerman P, Fryns JP et al. Fetal akinesia. sequence caused by nemaline myopathy. Neuropediatrics 1997;28:116-9.
9. Wallgren-Pettersson C, Laing NG. Report of the 70th ENMC International Workshop: Nemaline Myopathy. Neuromusc Disord 2000;10:299-306.
10. Laing NG, Majda BT, Akkari PA et al. Assignment of a gene (NEMI) for autosomal dominant nemaline myopathy to chromosome I. Am J Hum Genet 1992;50:576-83.
11. Laing NG, Wilton SD, Akkari PA et al. A mutation in the alpha tropomyosin gene TPM3 associated with autosomal-dominant nemaline myopathy. Nature Genet 1995;9:75-9.
12. Wallgren-Pettersson C, Avela K, Marchand S et al. A gene for autosomal recessive nemaline myopathy assigned to chromosome 2q by linkage analysis. Neuromusc Disord 1995;5:441-3.
13. Pelin K, Hilpelä F, Hanefeld F et al. Mutations in the nebulin gene associated with autosomal-recessive nemaline myopathy. Proc Natl Acad Sci USA 1999;96:2305-10.
14. Nowak KJ, Wattanasirichaigoon D, Goebel HH et al. Mutations in the skeletal muscle alpha actin gene in patients with actin myopathy and nemaline myopathy Nature Genet 1999;23:208-12.
15. Donner K, Ollikainen M, Ridanpaa M et al. Mutations in the beta-tropomyosin (TPM2) gene-a rare cause of nemaline myopathy. Neuromusc Disord 2002;12:151-8.
16. Johnston JJ, Kelley RI, Crawford TO et al. A novel nemaline myopathy in the Amish caused by a mutation in troponin T1. Am J Hum Genet 2000;67: 814-21.
17. Wallgren-Pettersson C, Donner K, Sewry C et al. Mutations in the nebulin gene can cause severe congenital nemaline myopathy. Neuromusc Disord 2002; 12:674.
18. Pelin K, Donner K, Holmberg M et al. Nebulin mutations in autosomal recessive nemaline myopathy: an update. Neuromusc Disord 2002;12:680.
19. Gurgel-Giannetti J, Reed U, Bang ML et al. Nebulin expression in patients with nemaline myopathy. Neuromusc Disord 2001;11:154-62.
20. Sewry CA, Brown SC, Pelin K et al. Abnormalities in the expression of nebuline in chromosome-2 linked nemaline myopathy. Neuromusc Disord 2001;11:146-53.
21. Ilkovski B, Cooper ST, Nowak K et al. Nemaline myopathy caused by mutations in the muscle α-skeletal actin gene. Am J Hum Genet 2001;68:1333-43.
22. Wattanasirichaigoon D, Swoboda KJ, Takada F et al. Mutations of the slow muscle alpha-tropomyosin gene, TPM3, are a rare cause of nemaline myopathy. Neurology 2002;59:613-7.
23. Tan P, Briner J, Boltshauser E et al. Homozygosity for a nonsense mutation in the alpha-tropomyosin gene TPM3 in a patient with severe nemaline myopathy. Neuromusc Disord 1999;9:573-9.
24. Michele DE, Albayya FP, Metzger JM. A nemaline mutation in α-tropomyosin causes defective regulation of striated muscle force production. J Clin Invest 1999;104:1575-81.
25. Michele DE, Coutu P, Metzger JM. Divergent abnormal muscle relaxation by hypertrophic cardiomyopathy and nemaline myopathy mutant tropomyosins. Physiol Genom 2002;9:103-11.
26. Scacheri PC, Hoffman EP, Fratkin JD et al. A novel ryanodine receptor mutation causing both cores and rods in congenital myopathy. Neurology 2000;55:1689-96.
27. Vita C, Migliorato A, Baradello A et al. Expression of cytoskeleton proteins in central core disease. J Neurol Sci 1994;124:71-6.
28. van der Ven F, Jap PH, ter Laak HJ et al. Immunophenotyping of congenital myopathies: disorganization of sarcomeric, cytoskeletal and extracellular matrix proteins. J Neurol Sci 1995;129:199-213.
29. Sewry CA. The role of immunocytochemistry in congenital myopathies. Neuromusc Disord 1998;8:394-400.
30. Sewry CA, Short DJ, Evans GA. The role of immunocytochemistry in the assessment of central core disease. Neuromusc Disord 2000;10:353. abstract.
31. Manzur AY, Sewry CA, Ziprin J et al. A severe clinical and pathological variant of central core disease with possible autosomal-recessive inheritance. Neuromusc Disord 1998;8:467-73.
32. Lamont PJ, Dubowitz V, Landon DN et al. Fifty year follow-up of a patient with central core disease shows slow but definite progression. Neuromusc Disord 1998;8:385-91.
33. Jungbluth H, Müller CR, Halliger-Keller B et al. Autosomal-recessive inheritance of RYR1 mutations in a congenital myopathy with cores. Neurology 2002;59:284-7.
34. Haan EA, Freemantle CJ, McCure JA et al. Assignment of the gene for central core disease to chromosome 19. Hum Genet 1990;86:187-90.
35. McCarthy T, Quane KA, Lynch PJ. Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mut 2000;15:410-7.
36. Jurkat-Rott K, McCarthy T, Lehmann-Horn F. Genetics and pathogenesis of malignant hyperthermia. Muscle Nerve 2000;23:4-17.
37. Takeshima H, Nishimura S, Matsumoto T et al. Primary structure and expression from complementary DNA of skeletal muscle ryanodine receptor. Nature 1989;339:439-45.
38. Fleischer S, Inui M. Biochemistry and biophysics of excitation-contraction coupling. Annu Rev Biophys Biophys Chem 1989;18:333-64.
39. Coronado R, Morrissette J, Sukhareva M, Vaughan DM. Structure and function of ryanodine receptors. Am J Physiol 1994;266:C1485-504.
40. Murray BE, Ohlendieck K. Cross-linking analysis of the ryanodine receptor and alpha-1-dihydropyridine receptor in rabbit skeletal muscle triads. Biochem J 1997;324:689-96.
41. Zhang Y, Chen HS, Khanna VK et al. A mutation in the human ryanodine receptor associated with central core disease. Nature Genet 1993;5:46-50.
42. Quane KA, Healy JM, Keating KE et al. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nature Genet 1993;5:51-5.
43. Quane KA, Keating KE, Healy JM et al. Mutation screening of the RYR1 gene in malignant hyperthermia: Detection of a novel Tyr to Ser mutation in a pedigree with associated central cores. Genomics 1994;23:236-9.
44. 2++ release channel function and severe central core disease. Proc Natl Acad Sci 1999;96:4164-9.
45. Tilgen N, Zorzato F, Halliger-Keller B et al. Identification of four novel mutations in the C-terminal membrane spanning domain of the ryanodine receptor 1: association with central core disease and alteration of calcium homeostasis. Hum Mol Genet 2001;10:2879-87.
46. Monnier N, Romero NB, Lerale J et al. Familial and sporadic forms of central core disease are associated with mutations in the C-terminal domain of the skeletal muscle ryanodine receptor. Hum Mol Genet 2001;10:2581-92.
47. Davis MR, Haan E, Jungbluth H et al. Principal mutation hotspot for central core disease and related myopathies in the C-terminal transmembrane region of the RYR1 gene. Neuromusc Disord 2003; in press.
48. Galli L, Orrico A, Cozzolino S et al. Mutations in the RYR1 gene in Italian patients at risk for malignant hyperthermia: evidence for a cluster of novel mutations in the C-terminal region. Cell Calcium 2002;32:143.
49. Sambuughin N, McWilliams S, de Bantel A et al. Single-amino-acid deletion in the RYR1 gene, associated with malignant hyperthermia susceptibility and unusual contraction phenotype. Am J Hum Genet 2001;69:204-8.
50. Ferreiro A, Monnier N, Romero NB et al. A recessive form of central core disease, transiently presenting as multi-minicore disease, is associated with a homozygous mutation in the ryanodine receptor type 1 gene. Ann Neurol 2002;51:750-9.
51. 2+ release of skeletal sarcoplasmic reticulum is responsible for hypersensitivity to caffeine and halothane in malignant hyperthermia. J Biol Chem 1994;269:9413-5.
52. 2+ transients in COS-7 transfected with the cDNA encoding skeletal muscle ryanodine receptor carrying a mutation associated with malignant hyperthermia. Biochem J 1994;301:661-5.
53. 2+ release is altered by 15 calcium release channel mutations associated with malignant hyperthermia and/or central core disease. J Biol Chem 1997;272:26332-9.
54. 2+ release channels. J Biol Chem 1999;274:693-702.
55. Avila G, O'Brien JJ, Dirksen RT. Excitation-contraction uncoupling by a human central core disease mutation in the ryanodine receptor. PNAS 2001;98:4215-20.
56. Ferreiro A, Fardeau M. 80th ENMC International Workshop on Multi-Minicore Disease: First International MmD Workshop, 12-13th May, 2000, Soestduinen, The Netherlands. Neuromusc Disord 2002;12:60-8.
57. Bethlem J, Arts WF, Koert P, Dingemans KP. Common origin of rods, cores miniature cores, and focal loss of cross-striations. Arch Neurol 1978;35:555-66.
58. Vallat JM, de Lumley L, Loubet A et al. Coexistence of minicores, cores, and rods in the same muscle biopsy. A new example of mixed congenital myopathy. Acta Neuropathol 1982;58:229-32.
59. De Cauwer H, Heytens L, Lubke U et al. Discordant light microscopic, electron microscopic, and in vitro contracture study findings in a family with central core disease. Clin Neuropathol 1997;16:237-42.
60. Jungbluth H, Sewry C, Brown SC et al. Minicore myopathy in children-a clinical and histopathological study of 19 cases. Neuromusc Disord 2000;10:264-73.
61. Ferreiro A, Estournet B, Chateau D et al. Multi-minicore disease-searching for boundaries: phenotype analysis of 38 cases. Ann Neurol 2000;48:745-57.
62. Rowe PW, Eagle M, Pollitt C et al. Multicore myopathy: respiratory failure and paraspinal muscle contractures are important complications. Dev Med Child Neurol 2000;42:340-3.
63. Moghadaszadeh B, Petit N, Jaillard C et al. Mutations in SEPN1 cause congenital muscular dystrophy with spinal rigidity and restrictive respiratory syndrome. Nature Genet 2001;29:17-18.
64. Ferreiro A, Quijano-Roy S, Pichereau C et al. Mutations of the selenoprotein N gene, which is implicated in rigid spine muscular dystrophy, cause the classical phenotype of multiminicore disease: Reassessing the nosology of early-onset myopathies. Am J Hum Genet 2002;71:739-49.
65. Barth PG, Dubowitz V. X-linked myotubular myopathy-a long-term follow-up study. Eur J Paediatr Neurol 1998;1:49-56.
66. Herman GE, Finegold M, Zhao W et al. Medical complications in long-term survivors with X-linked myotubular myopathy. J Pediatr 1999;134:206-14.
67. Wallgren-Pettersson C, Clarke A, Samson F et al. The myotubular myopathies: differential diagnosis of the X-linked recessive, autosomal dominant, and autosomal recessive forms and present state of DNA studies. J Med Genet 1995;32:673-9.
68. Laporte J, Hu LJ, Kretz C et al. A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast. Nat Genet 1996;13:175-82.
69. Laporte J, Biancalana V, Tanner SM et al. MTM1 mutations in X-linked myotubular myopathy. Hum Mutat 2000;15:393-409.
70. Laporte J, Kress W, Mandel JL. Diagnosis of X-linked myotubular myopathy by detection of myotubularin. Ann Neurol 2001;50:42-6.
71. Wallgren-Pettersson C. 72nd ENMC International Workshop: Myotubular Myopathy, Hilversum, The Netherlands, 1st to 3rd October 1999. Neuromusc Disord 2000;10:525-9.
72. Dahl L, Hu LJ, Chery M et al. Myotubular myopathy in a girl with a deletion of Xq27-q28 and unbalanced X-inactivation assigns the MTM1 gene to a 600-kb region. Am J Hum Genet 1995;56:1108-15.
73. Tanner SM, Orstavik KH, Kristiansen M et al. Skewed X-inactivation in a manifesting carrier of X-linked myotubular myopathy and in her non-manifesting carrier mother. Hum Genet 1999;104:249-53.
74. Jungbluth H, Sewry CA, Buj-Bello A et al. Early and severe presentation of X-linked myotubular myopathy in a girl with skewed X-inactivation. Neuromusc Disord 2003; 13:55-9.
75. Laporte J, Blondeau F, Buj-Bello A et al. Characterization of the myotubularin dual specifity phosphatase gene family from yeast to human. Hum Mol Genet 1998;7:1703-12.
76. Blondeau F, Laporte J, Bodin S et al. Myotubularin, a phosphatase deficient in myotubular myopathy, acts on phosphatidylinositol 3-kinase and phosphatidylinositol 3-phosphate pathway. Hum Mol Genet 2000;9:2223-9.